Biotech Company Polypid Aims to Raise $75 Million with Nasdaq IPO

Three years after a failed initial public offering attempt, Israel-based biotech company Polypid Ltd. set the terms for a new IPO in a filing with the U.S. Securities and Exchange Commission on Wednesday. The company is aiming to raise $75 million on Nasdaq by offering 3.33 million ordinary shares at $21-$24, according to the prospectus. The filing is an update to a prospectus the company filed in February. Polypid intends to list under the ticker POLY.

For daily updates, subscribe to our newsletter by clicking here.

 

Based on the prospectus, Polypid is looking to raise the money according to a pre-funding valuation of $275 million to $325 million.

Established in 2008 and based in Petach Tikva, a city in the Tel Aviv metropolitan area, Polypid is a clinical-stage company developing encapsulation technology for extended release, localized drug delivery. The technology could enable better control of problematic drugs like those that are sensitive to heat or pH levels or are toxic in large doses, improving both their safety and their performance.

The company intends to use the funding raised for clinical development and trials, and for manufacturing activities, according to the prospectus.

This is Polypid’s second IPO attempt. The company first tried listing three years ago at a valuation of $100 million, but withdrew its submission in early 2015. Polypid previously raised $22 million in 2016 at a $82 million valuation.

Goldman Sachs, Oppenheimer & Co., Cowen Inc., Cantor Fitzgerald & Co. and Raymond James Financial are the underwriters listed for the IPO. Polypid stated they have the option to purchase up to 500,000 additional ordinary shares at the initial price.